Europe Molecular Diagnostics Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 3.45 Billion |
| Market Size (2029) | USD 5.32 Billion |
| CAGR (2024 - 2029) | 8.96 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Europe Molecular Diagnostics Market Analysis
The Europe Molecular Diagnostics Market size is estimated at USD 3.45 billion in 2024, and is expected to reach USD 5.32 billion by 2029, growing at a CAGR of 8.96% during the forecast period (2024-2029).
Factors such as the increasing burden of various bacterial and viral epidemics in this region, increasing demand for point-of-care diagnostics, and recent advancements in pharmacogenomics are expected to propel market growth during the forecast period. For instance, in May 2023, the ECCMID congress ELITech Group announced the impending launch of a new high throughput sample-to-result instrument for molecular diagnostics. The company’s new high throughput approach will be based on ELITech’s proven extraction and assay technology.
Further, according to the European Alliance for Personalized Medicine December 2023 factsheet, the United Kingdom has a well-established infrastructure for NGS testing. There are dedicated NGS centers equipped with the necessary tools and infrastructure. Sufficient funding is available to develop and maintain NGS infrastructure, indicating a commitment to advancing this technology. Thus, the availability of infrastructure and advancing technology in Europe is anticipated to increase the adoption of molecular diagnostics in the region.
The market players in the region are concentrating on product and technological development and acquiring technology companies to boost market growth. For instance, in May 2024, Bruker Corporation acquired the ELITechGroup business, excluding the carved-out ELITech clinical chemistry business. ELITech provides systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology. Such developments are expected to drive the market.
Therefore, the market is anticipated to achieve high growth rates during the forecast period due to the above factors. However, the need for high-complexity testing centers is expected to hinder market growth during the forecast period.
Europe Molecular Diagnostics Market Trends
The Infectious Disease Segment is Expected to Witness High Growth During the Forecast Period
The infectious disease segment is anticipated to hold significant market shares during the forecast period. This segment is driven by the increased number of medicines developed and the European region's massive burden of infectious diseases. For instance, sexually transmitted infections (STIs) represent a significant public health problem in the United Kingdom.
According to LabMedica International, in December 2023, researchers developed a new artificial intelligence (AI)- an assisted molecular diagnostic platform that can identify infectious diseases. This cost-effective, portable device could be instrumental in curbing future pandemics due to its high accuracy and adaptability. Therefore, a rise in innovations in diagnostics of infectious diseases is expected to fuel market growth during the forecast period.
Moreover, key players in the region are expanding their regional market position by adopting various strategies, such as mergers and acquisitions, while others are developing new test methods for diagnosis and introducing new products to retain their market share. In September 2023, Professor Johnjoe McFadden's research team developed a new molecular test called "Electro-chemical LAMP" (eLAMP). This test is affordable, rapid, sensitive, and can be performed at home, in a GP surgery, or a hospital lab. eLAMP is sensitive to lab-based polymerase chain reaction (PCR) tests but can be performed at home when connected to a smartphone.
Therefore, the factors mentioned above are expected to drive segmental growth in the market during the forecast period.
Germany is Expected to Dominate the European Molecular Diagnostics Market
Germany has a strong base of global companies working on developing molecular diagnostics due to the increasing prevalence of chronic diseases and the rising geriatric population in the country, which is more prone to several chronic diseases. This is expected to drive market growth. The increasing incidence of chronic conditions, such as cancer in Germany, is expected to contribute to the development of the market. According to the Annals of Oncology report of 2023, about 1,261,990 cancer deaths were registered for 2023 in Europe. Breast and colorectum cancer were more prevalent in females, while in males, prostate and lung cancer were more prevalent in the country. The increasing prevalence of cancer conditions among the German population led to the rise in demand for molecular diagnostics, thereby contributing to the overall market growth during the forecast period.
The country's development will drive market growth during the forecast period. For instance, in January 2024, ELITechGroup launched CE-IVDR certified GI Bacterial PLUS ELITe MGB Kit, a robust addition to its diagnostic portfolio in Germany.
Thus, owing to the above factors, the market in Germany is expected to project growth during the forecast period.
Europe Molecular Diagnostics Industry Overview
The European molecular diagnostics market is fragmented due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known, including Abbott Laboratories, F Hoffmann-la Roche Ltd, Hologic Corporation, Danaher Corporation, and Agilent Technologies.
Europe Molecular Diagnostics Market Leaders
-
Abbott Laboratories
-
Hologic Corporation
-
Danaher Corporation
-
Agilent Technologies
-
F Hoffmann-la Roche Ltd
*Disclaimer: Major Players sorted in no particular order
Europe Molecular Diagnostics Market News
- Febraury 2024: Sysmex Corporation entered a strategic alliance agreement with CellaVision AB to advance hematology solutions by expanding its portfolio, including next-generation cell morphology analyzers.
- November 2023: F Hoffmann-la Roche Ltd launched the LightCycler PRO System based on the proven gold standard technology of the LightCycler Systems that came before it. This new system raises the bar for performance and usability while bridging the gap between translational research and in vitro diagnostics.
Europe Molecular Diagnostics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Point-of-care Diagnostics
4.2.2 Advancements in Pharmacogenomics and Other Technologies
4.2.3 Possibility of Outbreaks of Bacterial and Viral Epidemics
4.3 Market Restraints
4.3.1 Need for High-complexity Testing Centers
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value in USD)
5.1 By Technology
5.1.1 In Situ Hybridization
5.1.2 Chips and Microarrays
5.1.3 Mass Spectrometry (MS)
5.1.4 Sequencing
5.1.5 PCR
5.1.6 Other Technologies
5.2 By Application
5.2.1 Infectious Diseases
5.2.2 Oncology
5.2.3 Pharmacogenomics
5.2.4 Microbiology
5.2.5 Genetic Disease Testing
5.2.6 Other Applciations
5.3 By Product
5.3.1 Instruments
5.3.2 Reagents
5.3.3 Other Products
5.4 By End User
5.4.1 Hospitals
5.4.2 Laboratories
5.4.3 Other End Users
5.5 By Geography
5.5.1 Germany
5.5.2 United Kingdom
5.5.3 France
5.5.4 Italy
5.5.5 Spain
5.5.6 Rest of Europe
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Agilent Technologies
6.1.3 Becton, Dickinson and Company
6.1.4 Danaher Corporation
6.1.5 F Hoffmann-la Roche Ltd
6.1.6 Hologic Corporation
6.1.7 Illumina Inc.
6.1.8 Myriad Genetics
6.1.9 Qiagen NV
6.1.10 Thermo Fisher Scientific
6.1.11 Sysmex Corporation
6.1.12 bioMerieux SA
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Europe Molecular Diagnostics Industry Segmentation
Molecular diagnostic tests detect specific sequences in DNA or RNA (including single nucleotide polymorphisms (SNP), deletions, rearrangements, and insertions), which may or may not be associated with diseases.
The European molecular diagnostics market is segmented by technology, application, product, end user, and geography. By technology, the market is segmented into in situ hybridization, chips and microarrays, mass spectrometry (MS), sequencing, PCR, and other technologies. By application, the market is segmented into infectious diseases, oncology, pharmacogenomics, microbiology, genetic disease testing, and other applications. By product, the market is segmented into instruments, reagents, and other products. By end user, the market is segmented into hospitals, laboratories, and other end users. Geographically, the market is segmented into Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. The market report also covers the estimated market sizes and trends in Europe. The report offers market size and forecasts in value (USD) for the above segments.
| By Technology | |
| In Situ Hybridization | |
| Chips and Microarrays | |
| Mass Spectrometry (MS) | |
| Sequencing | |
| PCR | |
| Other Technologies |
| By Application | |
| Infectious Diseases | |
| Oncology | |
| Pharmacogenomics | |
| Microbiology | |
| Genetic Disease Testing | |
| Other Applciations |
| By Product | |
| Instruments | |
| Reagents | |
| Other Products |
| By End User | |
| Hospitals | |
| Laboratories | |
| Other End Users |
| By Geography | |
| Germany | |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe |
Europe Molecular Diagnostics Market Research FAQs
How big is the Europe Molecular Diagnostics Market?
The Europe Molecular Diagnostics Market size is expected to reach USD 3.45 billion in 2024 and grow at a CAGR of 8.96% to reach USD 5.32 billion by 2029.
What is the current Europe Molecular Diagnostics Market size?
In 2024, the Europe Molecular Diagnostics Market size is expected to reach USD 3.45 billion.
Who are the key players in Europe Molecular Diagnostics Market?
Abbott Laboratories, Hologic Corporation, Danaher Corporation, Agilent Technologies and F Hoffmann-la Roche Ltd are the major companies operating in the Europe Molecular Diagnostics Market.
Which is the fastest growing region in Europe Molecular Diagnostics Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Europe Molecular Diagnostics Market?
In 2024, the North America accounts for the largest market share in Europe Molecular Diagnostics Market.
What years does this Europe Molecular Diagnostics Market cover, and what was the market size in 2023?
In 2023, the Europe Molecular Diagnostics Market size was estimated at USD 3.14 billion. The report covers the Europe Molecular Diagnostics Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Europe Molecular Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Europe Molecular Diagnostics Industry Report
Statistics for the 2024 Europe Molecular Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Molecular Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
